1PASSWORD
4.6.2024 07:01:32 CEST | Business Wire | Press release
1Password, a leader in identity security, today announced significant business momentum across Europe, the Middle East, and Africa (EMEA). With a strategic focus on the region, 1Password is expanding its workforce, launching products tailored to the EMEA market, and securing over 35% of Europe’s Top 100 companies. Today, over one-third of 1Password’s B2B customers are based in EMEA.
The majority (68%) of security breaches are still caused by a human element resulting in compromised credentials, and the company recently launched 1Password Extended Access Management (XAM), an industry-first solution designed to secure every login to every app from every device, addressing the modern workforce’s need for even more seamless and secure access. Now available in the EMEA region, this solution protects users' privacy and gives businesses strong security across managed and unmanaged applications and devices, while offering visibility and insights to help them meet resilience, compliance, and audit goals. As a leading enterprise password manager, 1Password enhances identity security by providing businesses with secure access to their most sensitive information, such as login credentials and SSH keys, actionable insights to address vulnerabilities, and seamless integration with existing security infrastructure.
1Password recently hired Oliver Cheal as Vice President, EMEA. In this role, he will oversee the company’s EMEA-based teams that are focused on designing, developing, selling, and supporting 1Password’s identity and access management solutions for customers in the region. Cheal was most recently at Cisco and Duo Security and his background is in transforming cybersecurity businesses by leading organizational change and building out the go-to-market function. With more than 100 employees in EMEA, 1Password is actively investing in its EMEA workforce, with plans to open positions across sales, marketing, customer success, and partnerships in the UK, Netherlands, and Germany.
“I am thrilled to join 1Password at such a pivotal time and grow our EMEA team to better serve our customers across the region,” said Oliver Cheal, VP of EMEA. “With 1Password Extended Access Management, we're revolutionizing access management by bridging the gaps left by traditional IAM solutions. With its seamless integration and user-friendly design, we are able to empower IT and security teams with unparalleled visibility and control, ensuring their employees can safely use the tools they need, whether working remotely or in the office.”
Earlier this year, the company launched the 1Password Global Partner Program and the 1Password® Enterprise Password Manager - MSP Edition in beta to provide resellers, distributors, and Managed Service Providers (MSPs) with the tools and resources they need to help their customers become more secure. Key strategic partners in EMEA include Amazon Web Services (AWS), Arrow Electronics, Insight Enterprises, Tap.De, and SVA.
“Watching 1Password's expansion into EMEA is incredibly exciting. Their growth and vision have always perfectly aligned with ours, and we are thrilled to be part of this journey, supporting their success every step of the way. By addressing critical security gaps with their new Extended Access Management (XAM) solution, 1Password is pioneering a new category in cybersecurity that ensures comprehensive protection across the modern, hybrid work environment and we are excited to be their partner,” said Ikramul Khaled, the Group Head of Vendor Alliances at QBS Technology Group.
For more information about 1Password, visit our website here.
About 1Password
Trusted by over 150,000 businesses and millions of consumers, 1Password offers identity security and access management solutions built for the way people work and live today. 1Password is on a mission to eliminate the conflict between security and productivity while securing every sign-in for every app on every device. As the provider of the most-used enterprise password manager, 1Password continues to innovate on its strong foundation to offer security solutions relied upon by companies of all sizes, including Associated Press, Salesforce, GitLab, Under Armour, and Intercom.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603036115/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
